Good morning,
Poland is a leading pet-friendly country. According to a FEDIAF report, the percentage of households with at least one dog reaches 49%. This is the second-highest figure in the EU. “Dog” is no longer just clickbait; it’s a true reflection of a social trend. The dynamics of the global market are driven by both the growing number of pets and their owners’ tendency to “premiumize” products, including increasingly higher expectations for therapeutic products.
At Bioceltix, we love animals, and we express our care and dedication by intensively working on medicines that will improve the quality and comfort of life for our four-legged friends. Our three main products have already undergone clinical trials, and for two of them: BCX-CM-J for osteoarthritis in dogs and BCX-EM for arthritis in horses, we are in constructive dialogue with the European market regulator. Thanks to recent successful events, we can maintain our development momentum and implement our plan to produce future medicines for the world.
In the meantime – a roundup of the latest news from Bioceltix!
As a result of the successful share offering, we will raise nearly PLN 53 million gross. This cash injection will help us, among other things, maintain the pace of construction of our new facility – the largest animal stem cell production facility in the world. We are pleased that investors appreciated our ambitious plans, allowing us to easily place the entire offering. The success of the transaction was made possible with the support of the shareholders who offered their shares for sale: Alternative Solution ASI and Kvarko Group ASI. “I wish every management board such stable shareholders who prioritize the company’s interests over their own in their investment plans. I am pleased that during the offering, we saw not only strong demand for our shares but also a large number of entities interested in participating. This means that the group of financial institutions supporting us is constantly growing, which is good news,” says Paweł Wielgus. | Read more
The excellent final results of the clinical trial of BCX-CM-AD confirm the potential of our therapies for combating autoimmune and inflammatory diseases using stem cells. We have demonstrated the product’s safety and effectiveness in treating atopic dermatitis in the short, medium, and long term. A single administration of BCX-CM-AD significantly alleviated skin lesions in patients after less than a month, and the therapeutic effect lasted up to three months after administration. The product’s strong anti-inflammatory effects led to faster improvement of skin lesions in dogs, and consequently, itching subsided. This also motivates us to develop the product for the treatment of other diseases in the future, including inflammatory bowel disease and chronic kidney disease. | Read more
We recently held a number of fruitful international discussions. We presented groundbreaking biotechnology solutions, proudly made in Poland, to scientists at the “European Congress of Veterinary Internal Medicine for Companion Animals” in Maastricht. At the end of October, we were in Frankfurt for the Polish Corporate Summit. We had the opportunity to talk about Bioceltix to numerous institutional and private investors, and the event culminated in networking and discussions about how innovations, including those under the biotechnology umbrella, are driving our country’s economic growth.
Is Wrocław the jewel in the crown? Perhaps. In the heart of Lower Silesia, we are shaping the future of veterinary biotechnology. And we are currently expanding our team. Join us and work on cell therapies that transform the lives of animals. Ongoing recruitment: Job offers – Pracuj.pl
This is the talk of the town in Poland and around the world:
New therapeutic areas, including kidney disease, heart disease, and cancer, are part of Zoetis’s business expansion plans. The company’s CEO, Kristin Peck, recently emphasized that modern therapies specifically targeting kidney disease in companion animals currently represent a huge and still untapped market opportunity, worth as much as $3-4 billion. Zoetis, a global leader in veterinary biologics, announces the introduction of new medicinal products in additional segments over the next two years. The company’s management also points to the growing importance of dermatology, pain management, and antiparasitic products as significant pillars of the overall animal health market. Zoetis’s strategy confirms the direction Bioceltix has chosen – especially the trend of seeking biological solutions for additional disease entities, including nephrology. | Read more
We’re at the peak of our market momentum when it comes to the development of veterinary biotechnology. We’re supported not only by the forecasts of leading industry players, but also by the willingness of pet owners to invest in advanced, more effective, and safer treatment methods. According to data from the European Pet Food Industry Federation, one in four households in Europe has a dog. And in Poland? A dog already lives in every second home. In the FEDIAF ranking, we rank second in the EU, right after Hungary. A symptom of deeper social changes is discussed in an interesting analysis by XYZ.pl. | Read more
The data suggests that, from a business perspective, the sale of pet toys may have more potential than the sale of children’s toys. We already know that the population of people under 18 in Poland reaches 7.2 million, and the number of dogs is 8.4 million. It’s no surprise that even e-commerce companies are increasingly expanding their operations to include pet products. The results are visible: at the German company Foodora, orders for pet products have doubled over the past three years, with a 30% year-on-year increase between February 2024 and February 2025. Meanwhile, Glovo, a Spanish company also known in Poland, recorded a 70% increase in sales in July 2025 compared to the same period in 2024. The number of partnerships with retailers offering pet supplies has also increased, from around 30 to over 100. What’s driving the boom? | Read more
“Your dog is now a full-fledged member of the family,” the New York Supreme Court recently ruled. In a landmark ruling, with legal implications reaching from Bushwick, New York, to the Bronx, the judge ruled that, under the law, dogs are no longer “property” but “immediate family.” The decision stems from the distressing case of Duke, a dachshund, who was fatally hit by a car while walking his pet sitter. The court ruled that a person walking a pet on a leash can seek compensation for non-pecuniary damages (e.g., emotional distress) – previously reserved only for family members. | Read more
Alongside dogs and horses, cats hold a special place in our hearts. Did you know that individuals with pale blue eyes carry a mutation that inhibits pigment production even during embryonic development? This is precisely why their eyes have such a distinctive, cool hue. Instead of being absorbed by the iris, light reflects off its molecules, creating a piercing blue effect. We encourage you to gaze into the eyes of cats captured in the exceptional photographs in the recently published book “Feline.” | Read more
We publish even more industry news and current information about our progress on LinkedIn – we invite you to follow the Bioceltix profile.
If you have any suggestions for the newsletter content, please contact us: newsletter@bioceltix.com.
Best regards,
The Bioceltix Team
MACHINE TRANSLATION